| Item Type | Name |
|
Concept
|
Disease-Free Survival
|
|
Concept
|
Survival Rate
|
|
Concept
|
Survival Analysis
|
|
Academic Article
|
Gynecologic Oncology Group risk groups for vulvar carcinoma: improvement in survival in the modern era.
|
|
Academic Article
|
Pathologic findings and outcomes for octogenarians presenting with uterine malignancy.
|
|
Academic Article
|
Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group.
|
|
Academic Article
|
Recurrence and survival after random assignment to laparoscopy versus laparotomy for comprehensive surgical staging of uterine cancer: Gynecologic Oncology Group LAP2 Study.
|
|
Academic Article
|
Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.
|
|
Academic Article
|
CT Perfusion as an Early Biomarker of Treatment Efficacy in Advanced Ovarian Cancer: An ACRIN and GOG Study.
|
|
Academic Article
|
Comparison of clinical versus surgical staging systems in vulvar cancer.
|
|
Academic Article
|
Analysis of FIGO Stage IIIc endometrial cancer patients.
|
|
Academic Article
|
Surgical-pathological predictors of disease-free survival and risk groupings for IB2 cervical cancer: do the traditional models still apply?
|
|
Academic Article
|
Validation of FACT/GOG-AD subscale for ovarian cancer-related abdominal discomfort: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
|
|
Academic Article
|
A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Lapatinib and potential prognostic value of EGFR mutations in a Gynecologic Oncology Group phase II trial of persistent or recurrent endometrial cancer.
|
|
Academic Article
|
Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Risk factors for GI adverse events in a phase III randomized trial of bevacizumab in first-line therapy of advanced ovarian cancer: A Gynecologic Oncology Group Study.
|
|
Academic Article
|
Expression Patterns of the Wnt Pathway Inhibitors Dickkopf3 and Secreted Frizzled-Related Proteins 1 and 4 in Endometrial Endometrioid Adenocarcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Update on Intraperitoneal Chemotherapy for the Treatment of Epithelial Ovarian Cancer.
|
|
Academic Article
|
Does time interval between surgery and intraperitoneal chemotherapy administration in advanced ovarian cancer carry a prognostic impact? An NRG Oncology/Gynecologic Oncology Group study ancillary study.
|
|
Academic Article
|
Impact of histology and surgical approach on survival among women with early-stage, high-grade uterine cancer: An NRG Oncology/Gynecologic Oncology Group ancillary analysis.
|
|
Academic Article
|
A phase I study of intravenous or intraperitoneal platinum based chemotherapy in combination with veliparib and bevacizumab in newly diagnosed ovarian, primary peritoneal and fallopian tube cancer.
|
|
Academic Article
|
Secondary Surgical Cytoreduction for Recurrent Ovarian Cancer.
|
|
Academic Article
|
A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference?
|
|
Academic Article
|
Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study.
|
|
Academic Article
|
A randomized phase III trial of VH fibrin sealant to reduce lymphedema after inguinal lymph node dissection: a Gynecologic Oncology Group study.
|
|
Academic Article
|
Phase III study of valspodar (PSC 833) combined with paclitaxel and carboplatin compared with paclitaxel and carboplatin alone in patients with stage IV or suboptimally debulked stage III epithelial ovarian cancer or primary peritoneal cancer.
|
|
Academic Article
|
Serum profiling to distinguish early- and late-stage ovarian cancer patients from disease-free individuals.
|
|
Academic Article
|
Do uterine risk factors or lymph node metastasis more significantly affect recurrence in patients with endometrioid adenocarcinoma?
|
|
Academic Article
|
Intraperitoneal chemotherapy requires expertise and should be the standard of care for optimally surgically resected epithelial ovarian cancer patients.
|
|
Academic Article
|
The impact of obesity on surgical staging, complications, and survival with uterine cancer: a Gynecologic Oncology Group LAP2 ancillary data study.
|
|
Academic Article
|
Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer.
|
|
Academic Article
|
Randomized phase IIB evaluation of weekly paclitaxel versus weekly paclitaxel with oncolytic reovirus (Reolysin®) in recurrent ovarian, tubal, or peritoneal cancer: An NRG Oncology/Gynecologic Oncology Group study.
|
|
Academic Article
|
Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study.
|
|
Academic Article
|
Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma.
|
|
Academic Article
|
Method and timing of tumor volume measurement for outcome prediction in cervical cancer using magnetic resonance imaging.
|
|
Academic Article
|
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
|
|
Academic Article
|
Comparison of outcome measures in patients with advanced squamous cell carcinoma of the vulva treated with surgery or primary chemoradiation.
|
|
Academic Article
|
Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.
|
|
Academic Article
|
Pathologic and Treatment Outcomes Among a Geriatric Population of Endometrial Cancer Patients: An NRG Oncology/Gynecologic Oncology Group Ancillary Data Analysis of LAP2.
|
|
Academic Article
|
Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial.
|
|
Academic Article
|
Randomized phase II trial of bevacizumab plus everolimus versus bevacizumab alone for recurrent or persistent ovarian, fallopian tube or peritoneal carcinoma: An NRG oncology/gynecologic oncology group study.
|
|
Academic Article
|
Management of endometrial cancer with suspected cervical involvement.
|
|
Academic Article
|
Epidermal growth factor receptor in vulvar malignancies and its relationship to metastasis and patient survival.
|
|
Academic Article
|
Prognostic significance of ethnicity and age in advanced stage epithelial ovarian cancer: An NRG oncology/gynecologic oncology group study.
|
|
Academic Article
|
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study.
|